PRODUCTS SERVICES COMPANY CONTACT FAQ

Search Dictionary Mobile

Login

EMA-CO protocol

Subscribe to Selected New Research on EMA-CO protocol

2 relevant articles (1 outcomes, 0 trials/studies) found for this Bio-Agent

Description: chemotherapy protocol containing etoposide, methotrexate & dactinomycin (EMA) , vincristine & cyclophosphamide (CO); EMA & CO are given on alternate weeks; for therapy of gestational trophoblastic tumors

Relationship Network

Bio-Agent Context: Research Results

-

Therapeutics: 5215

-

Drug Therapy: 116820

-

Combination Drug Therapy: 8327

-

Antineoplastic Combined Chemotherapy Protocols: 16

*

EMA-CO protocol: 2

-

Antineoplastic Protocols: 20

-

Antineoplastic Combined Chemotherapy Protocols: 16

*

EMA-CO protocol: 2

-

Clinical Protocols

-

Antineoplastic Protocols: 20

-

Antineoplastic Combined Chemotherapy Protocols: 16

*

EMA-CO protocol: 2

-

Polycyclic Compounds: 58

-

Aromatic Polycyclic Hydrocarbons: 581

-

Naphthalenes: 10

-

Tetrahydronaphthalenes: 1

-

Podophyllotoxin: 336

-

Etoposide: 6693

*

EMA-CO protocol: 2

-

Macrocyclic Compounds: 1

-

Cyclic Peptides: 41

-

Dactinomycin: 1683

*

EMA-CO protocol: 2

-

Amino Acids, Peptides, and Proteins

-

Peptides: 16094

-

Cyclic Peptides: 41

-

Dactinomycin: 1683

*

EMA-CO protocol: 2

-

Carbohydrates: 2948

-

Glycosides: 341

-

-

Etoposide: 6693

*

EMA-CO protocol: 2